Overview of Liquidia Corporation's Upcoming Presentation
Liquidia Corporation (NASDAQ: LQDA), a pioneering biopharmaceutical company based in Morrisville, specializes in developing cutting-edge therapies for individuals suffering from rare cardiopulmonary diseases. Recently, the company announced that it will showcase significant clinical findings from its ASCENT trial during the upcoming CHEST 2025 Annual Meeting, scheduled from October 19 to October 22 in Chicago.
Details of the Presentations at the CHEST 2025 Annual Meeting
Liquidia is excited to present two oral sessions focused on groundbreaking data from the ASCENT trial. This trial primarily examines the safety and exploratory efficacy of LIQ861 DPI treprostinil, particularly in patients diagnosed with pulmonary hypertension associated with interstitial lung disease (PH-ILD). Additionally, the presentations will highlight observed changes in the cardiac effort of the PH-ILD population at Week 16 of the study.
The presentations will include:
Rapid Fire Oral Presentation
Scheduled for Tuesday, October 21, 2025, from 10:20 a.m. to 10:24 a.m. CT, titled "Changes in Cardiac Effort in Pulmonary Hypertension-Interstitial Lung Disease: Insights from ASCENT". The presenter will be Dr. Dan Lachant from the University of Rochester Medical Center. This session falls under the theme of seeking new diagnostic and monitoring approaches for pulmonary hypertension.
Late-Breaking Rapid Fire Oral Presentation
Also on October 21, from 1:52 p.m. to 1:57 p.m. CT, the topic will be "Safety and Exploratory Efficacy Data of LIQ861 DPI Treprostinil in PH-ILD: ASCENT to Week 16". This presentation will be delivered by Dr. Nicholas Kolaitis of the University of California, San Francisco (UCSF) Medical Center, during a session focused on advances in pharmacotherapy in pulmonary fibrosis.
Insights from the ASCENT Trial
The ASCENT trial is pivotal in understanding the administration of LIQ861, a novel therapy aimed at patients with WHO Group 1 and Group 3 pulmonary hypertension. This open-label, multi-center study, identified by ClinicalTrials.gov ID NCT06129240, focuses on evaluating the safety and tolerability of LIQ861 among patients with PH-ILD. The initial cohort includes 54 patients, and future protocol amendments may introduce additional cohorts from Group 1 or Group 3, contingent upon study needs.
During the trial, patients will undergo scheduled clinic visits at Screening, Baseline, Week 8, Week 16, Week 24, and Week 52, with the flexibility of dose titration based on the Investigator’s discretion. The primary aim of this study is centered around ensuring the safety and tolerability of LIQ861 among participants suffering from pulmonary hypertension, while exploratory objectives will evaluate effects relating to exercise capacity, relevant biomarkers, and imaging assessments.
About YUTREPIA™ and Liquidia Corporation
YUTREPIA, the inhaled dry-powder form of treprostinil developed by Liquidia, is designed for effortless delivery via a compact device, aimed at improving exercise capacity for patients with pulmonary arterial hypertension and PH-ILD. The drug was developed using Liquidia’s proprietary PRINT technology, which optimizes drug particle size and improves deposition in the lungs following inhalation. Though it was originally referred to as LIQ861, YUTREPIA represents an advancement in therapeutic options for these challenging conditions.
Liquidia Corporation continues to make strides in the biopharmaceutical industry, working diligently on innovative solutions for cardiopulmonary diseases. Presently, the company is developing L606, an investigational sustained-release formulation of treprostinil administered twice daily via a next-generation nebulizer. Liquidia also offers a generic version of Treprostinil Injection, catering to patients in need of treatment for pulmonary arterial hypertension.
To stay updated on the findings from the CHEST 2025 meeting, individuals can visit Liquidia's Publications page, where presentation materials will be made accessible following the event.
Frequently Asked Questions
What is the purpose of Liquidia's ASCENT trial?
The ASCENT trial aims to evaluate the safety and tolerability of LIQ861, a new therapy for patients with pulmonary hypertension.
What will Liquidia present at the CHEST 2025 meeting?
Liquidia will present two oral presentations highlighting significant data from the ASCENT trial related to patient safety and cardiac effort.
When is the CHEST 2025 Annual Meeting?
The CHEST 2025 Annual Meeting will take place from October 19 to October 22 in Chicago.
Who are the presenters for the ASCENT trial data?
The presentations will be delivered by Dr. Dan Lachant and Dr. Nicholas Kolaitis from the University of Rochester Medical Center and UCSF Medical Center, respectively.
What is YUTREPIA™?
YUTREPIA is an inhaled dry powder formulation of treprostinil that helps improve exercise ability in patients with pulmonary hypertension associated with interstitial lung disease.
